
Regulatory
Latest Content

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pharmaceutical Executive Daily: White House Withdraws FDA Nomination For Dr. Heidi Overton’s

White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report

Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo

The Workload Balance in Pharma Between Humans and Agentic Models

Shorts









Podcasts
Videos
All News

Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.

Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.

FDA submitted approvals for Novartis’s Cosentyx and Roche’s Wilserdly.

Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers whenever information is needed.

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

Pharma field forces face three key challenges: scaling services beyond tier one, shifting from reactive to proactive engagement, and empowering teams with agentic AI.

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.





















